Clinical Trial Update: A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating the safety and efficacy of combining Pexa-Vec with nivolumab in first-line advanced hepatocellular carcinoma; the study is terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pexa-Vec (pexastimogene devacirep)
• nivolumab (nivolumab)

Snippet

Sponsor: Transgene | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-11-19